STOCK TITAN

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
BioAtla, Inc. (Nasdaq: BCAB) announces an upcoming poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will focus on the Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab for advanced solid tumors.
BioAtla, Inc. (Nasdaq: BCAB) annuncia una futura presentazione di un poster al Congresso Annuale 2024 della Società Americana di Oncologia Clinica (ASCO). La presentazione si concentrerà sullo studio di Fase 1 del BA3071, un biologico attivo condizionatamente anti-CTLA-4, in combinazione con il nivolumab per tumori solidi avanzati.
BioAtla, Inc. (Nasdaq: BCAB) anuncia una próxima presentación de póster en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO) de 2024. La presentación se centrará en el estudio de Fase 1 de BA3071, un biológico condicionalmente activo anti-CTLA-4, en combinación con nivolumab para tumores sólidos avanzados.
BioAtla, Inc. (Nasdaq: BCAB)는 2024년 미국 임상 종양학회(ASCO) 연례 회의에서 포스터 발표를 진행할 예정이라고 발표했습니다. 이 발표는 BA3071, 항-CTLA-4 조건부 활성 생물학적 제제와 니볼루맙을 결합한 고형암에 대한 1상 연구에 초점을 맞출 것입니다.
BioAtla, Inc. (Nasdaq: BCAB) annonce une future présentation sous forme de poster lors de la réunion annuelle 2024 de la Société Américaine d'Oncologie Clinique (ASCO). La présentation portera sur l'étude de phase 1 de BA3071, un biologique actif conditionnel contre CTLA-4, en combinaison avec le nivolumab pour les tumeurs solides avancées.
BioAtla, Inc. (Nasdaq: BCAB) kündigt eine bevorstehende Posterpräsentation auf der Jahresversammlung 2024 der Amerikanischen Gesellschaft für Klinische Onkologie (ASCO) an. Die Präsentation wird sich auf die Phase-1-Studie von BA3071, einem bedingt aktiven biologischen Mittel gegen CTLA-4, in Kombination mit Nivolumab für fortgeschrittene feste Tumore konzentrieren.
Positive
  • None.
Negative
  • None.

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Presentation Details:

Title:     Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors
Authors: Jacob Stephen Thomas, Jennifer Eva Selfridge, Costantine Albany, Matthew Taylor, Inderjit Mehmi, Vineet Kwatra, Siwen Hu-Lieskovan, Paul De Souza, Judith Llorin-Sangalang, Kartik Aysola, Omid Hamid
Abstract Number: 2602
Session Type: Poster
Session Title: Developmental Therapeutics – Immunotherapy
Session Date and Time: Saturday, June 1, 2024; 9:00 AM – 12:00 PM CDT

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.

About BioAtla®, Inc. 

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 485 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. BioAtla submitted an IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company’s first glycoconjugate. To learn more about BioAtla, Inc. visit www.bioatla.com


FAQ

What is the upcoming event mentioned in the press release?

BioAtla, Inc. (BCAB) announced an upcoming poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

What is the focus of the poster presentation at the ASCO Annual Meeting?

The presentation will focus on the Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab for advanced solid tumors.

Where will the ASCO Annual Meeting take place?

The ASCO Annual Meeting will be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Where can the presentation materials be accessed?

The presentation materials can be accessed on the 'Publication' section of BioAtla's website at www.bioatla.com after the presentation concludes.

BioAtla, Inc.

NASDAQ:BCAB

BCAB Rankings

BCAB Latest News

BCAB Stock Data

74.32M
48.35M
10.75%
50.66%
10.85%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO